Immunogenicity of heparin-binding hemagglutinin expressed by Pichia pastoris GS115 strain

Document Type: Original Article


Department of Clinical Laboratory, Shandong International Travel Healthcare Center, Qingdao, China


Objective(s): Heparin-binding hemagglutinin (HBHA), a mycobacterial cell surface protein, mediates adhesion to nonphagocytic cells and the dissemination of Mycobacterium tuberculosis (M. tuberculosis) from the site of primary infection. Superior expression systems are required to obtain abundant M. tuberculosis proteins for the purpose of diagnosing M. tuberculosis infection or for the immunization. Here,  HBHA was expressed by Pichia pastoris (P. pastoris) GS115 strain , and the  immunogenicity of  HBHA was evaluated.
Materials and Methods: The HBHA gene of M. tuberculosis was cloned into the pPIC9K plasmid, which was good for electroporation into P. pastoris GS115 strain. Unlabeled HBHA protein was purified using a Sepharose CL-6B column, and its expression was confirmed using anti-HBHA polyclonal antibody from mouse serum. We injected C57BL/6 mice with HBHA/ dimethyldioctadecylammonium/trehalose 6,6′-dibehenate (HBHA/DDA/TDB) to investigate the immunogenicity of this potential vaccine.
Results: The results demonstrated that HBHA/DDA/TDB has the ability to induce high levels of HBHA-specific IgG antibody and its subclasses, as well as interferon-gamma, compared with injection of phosphate-buffered saline, DDA/TDB alone and Bacillus Calmette-Guérin (BCG) controls (P<0.05). Moreover, the ratio of IgG2a/IgG1 of the HBHA/DDA/TDB group was higher than that of the BCG group (P<0.05).
Conclusion: HBHA with no label has excellent immunogenicity, and is suitable for evaluating the effectiveness to prevent M. tuberculosis infection.


Main Subjects

1. World Health Organization. Global tuberculosis report 2016. Geneva: World Health Organization; 2016.

2. de Souza GA, Wiker HG. A proteomic view of Mycobacteria. Proteomics 2011; 11:3118-3127.

3. Ernst JD, Trevejo-Nunez G, Banaiee N. Genomics and the evolution, pathogenesis, and diagnosis of tuberculosis. J Clin Invest 2007; 117:1738-1745.

4. Menozzi FD, Bischoff R, Fort E, Brennan MJ, Locht C. Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin. Proc Natl Acad Sci U S A 1998; 95:12625-12630.

5. Masungi C, Temmerman S, Van Vooren JP, Drowart A, Pethe K, Menozzi FD, et al. Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis 2002; 185:513-520.

6. Pethe K, Alonso S, Biet F, Delogu G, Brennan MJ, Locht C, et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 2001; 412:190-194.

7. Menozzi FD, Rouse JH, Alavi M, Laude-Sharp M, Muller J, Bischoff R, et al. Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med 1996; 184:993-1001.

8. Parra M, Pickett T, Delogu G, Dheenadhayalan V, Debrie AS, Locht C, et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 2004; 72:6799-6805.

9. Guerrero GG, Locht C. Recombinant HBHA boosting effect on BCG-induced immunity against Mycobacterium tuberculosis infection. Clin Dev Immunol 2011; 2011:730702.

10. Temmerman S, Pethe K, Parra M, Alonso S, Rouanet C, Pickett T, et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med 2004; 10:935-941.

11. Hougardy JM, Schepers K, Place S, Drowart A, Lechevin V, Verscheure V, et al. Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS One 2007; 2:e926.

12. Temmerman ST, Place S, Debrie AS, Locht C, Mascart F. Effector functions of heparin-binding hemagglutinin-specific CD8+ T lymphocytes in latent human tuberculosis. J Infect Dis 2005; 192:226-232.

13. Belay M, Legesse M, Mihret A, Ottenhoff TH, Franken KL, Bjune G, et al. IFN-gamma and IgA against non-methylated heparin-binding hemagglutinin as markers of protective immunity and latent tuberculosis: results of a longitudinal study from an endemic setting. J Infect 2016; 72:189-200.

14. Delogu G, Bua A, Pusceddu C, Parra M, Fadda G, Brennan MJ, et al. Expression and purification of recombinant methylated HBHA in Mycobacterium smegmatis. FEMS Microbiol Lett 2004; 239:33-39.

15. Andersson GE, Sharp PM. Codon usage in the Mycobacterium tuberculosis complex. Microbiology 1996; 142:915-925.

16. Cregg JM, Cereghino JL, Shi J, Higgins DR. Recombinant protein expression in Pichia pastoris. Mol Biotechnol 2000; 16:23-52.

17. Giga-Hama Y, Kumagai H. Foreign gene expression in fission yeast S. pombe. Seikagaku 1998; 70:300-304.

18. Lin-Cereghino GP, Stark CM, Kim D, Chang J, Shaheen N, Poerwanto H, et al. The effect of alpha-mating factor secretion signal mutations on recombinant protein expression in Pichia pastoris. Gene 2013; 519:311-317.

19. Macauley-Patrick S, Fazenda ML, McNeil B, Harvey LM. Heterologous protein production using the Pichia pastoris expression system. Yeast 2005; 22:249-270.

20. Teng X, Tian M, Li J, Tan S, Yuan X, Yu Q, et al. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine. Hum Vaccin Immunother 2015; 11:1456-1464.

21. Locht C, Hougardy JM, Rouanet C, Place S, Mascart F. Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis (Edinb) 2006; 86:303-309.

22. Fukui M, Shinjo K, Umemura M, Shigeno S, Harakuni T, Arakawa T, et al. Enhanced effect of BCG vaccine against pulmonary Mycobacterium tuberculosis infection in mice with lung Th17 response to mycobacterial heparin-binding hemagglutinin adhesin antigen. Microbiol Immunol 2015; 59:735-743.

23. Guerrero GG, Debrie AS, Locht C. Boosting with mycobacterial heparin-binding haemagglutinin enhances protection of Mycobacterium bovis BCG-vaccinated newborn mice against M. tuberculosis. Vaccine 2010; 28:4340-4347.

24. Stylianou E, Diogo GR, Pepponi I, van Dolleweerd C, Arias MA, Locht C, et al. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. Eur J Immunol 2014; 44:440-449.

25. Verwaerde C, Debrie AS, Dombu C, Legrand D, Raze D, Lecher S, et al. HBHA vaccination may require both Th1 and Th17 immune responses to protect mice against tuberculosis. Vaccine 2014; 32:6240-6250.

26. Zhao S, Zhao Y, Mao F, Zhang C, Bai B, Zhang H, et al. Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice. PLoS One 2012; 7:e31908.

27. Zanetti S, Bua A, Delogu G, Pusceddu C, Mura M, Saba F, et al. Patients with pulmonary tuberculosis develop a strong humoral response against methylated heparin-binding hemagglutinin. Clin Diagn Lab Immunol 2005; 12:1135-1138.

28. Kohama H, Umemura M, Okamoto Y, Yahagi A, Goga H, Harakuni T, et al. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in infected mice. Vaccine 2008; 26:924-932.

29. Hutchinson P, Barkham TM, Tang W, Kemeny DM, Chee CB, Wang YT. Measurement of phenotype and absolute number of circulating heparin-binding hemagglutinin, ESAT-6 and CFP-10, and purified protein derivative antigen-specific CD4 T cells can discriminate active from latent tuberculosis infection. Clin Vaccine Immunol 2015; 22:200-212.

30. Loxton AG, Black GF, Stanley K, Walzl G. Heparin-binding hemagglutinin induces IFN-gamma(+) IL-2(+) IL-17(+) multifunctional CD4(+) T cells during latent but not active tuberculosis disease. Clin Vaccine Immunol 2012; 19:746-751.

31. Wyndham-Thomas C, Corbiere V, Dirix V, Smits K, Domont F, Libin M, et al. Key role of effector memory CD4+ T lymphocytes in a short-incubation heparin-binding hemagglutinin gamma interferon release assay for the detection of latent tuberculosis. Clin Vaccine Immunol 2014; 21:321-328.

32. Wyndham-Thomas C, Dirix V, Schepers K, Martin C, Hildebrand M, Goffard JC, et al. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube. BMC Infect Dis 2015; 15:59.

33. Delogu G, Chiacchio T, Vanini V, Butera O, Cuzzi G, Bua A, et al. Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders. PLoS One 2011; 6:e18315.

34. Rahman MJ, Fernandez C. Neonatal vaccination with Mycobacterium bovis BCG: potential effects as a priming agent shown in a heterologous prime-boost immunization protocol. Vaccine 2009; 27:4038-4046.

35. Rouanet C, Debrie AS, Lecher S, Locht C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 2009; 11:995-1001.

36. Soleimanpour S, Farsiani H, Mosavat A, Ghazvini K, Eydgahi MR, Sankian M, et al. APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice. Appl Microbiol Biotechnol 2015; 99:10467-10480.

37. Mosavat A, Soleimanpour S, Farsiani H, Sadeghian H, Ghazvini K, Sankian M, et al. Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine. Infect Genet Evol 2016; 39:163-172.

38. Farsiani H, Mosavat A, Soleimanpour S, Sadeghian H, Akbari EM, Ghazvini K, et al. Fc-based delivery system enhances immunogenicity of a tuberculosis subunit vaccine candidate consisting of the ESAT-6:CFP-10 complex. Mol Biosyst 2016; 12:2189-2201.

39. Kebriaei A, Derakhshan M, Meshkat Z, Eidgahi MR, Rezaee SA, Farsiani H, et al. Construction and immunogenicity of a new Fc-based subunit vaccine candidate against Mycobacterium tuberculosis. Mol Biol Rep 2016; 43:911-922.

40. Baghani AA, Soleimanpour S, Farsiani H, Mosavat A, Yousefi M, Meshkat Z, et al. CFP10: mFcƴ2 as a novel tuberculosis vaccine candidate increases immune response in mouse. Iran J Basic Med Sci 2017; 20:122-130.

41. Kang JJ, Lyu Y, Zhao DM, Tian LH, Yin XM, Yang LF, et al. Antimicrobial activity of recombinant mature bovine neutrophil beta-defensin 4 on mycobacterial infection. Int J Tuberc Lung Dis 2015; 19:711-716.

42. Kang J, Zhao D, Lyu Y, Tian L, Yin X, Yang L, et al. Antimycobacterial activity of Pichia pastoris-derived mature bovine neutrophil beta-defensins 5. Eur J Clin Microbiol Infect Dis 2014; 33:1823-1834.

43. Hwang SA, Wilk K, Kruzel ML, Actor JK. A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice. Vaccine 2009; 27:3026-3034.

44. Su C, Duan X, Wang X, Wang C, Cao R, Zhou B, et al. Heterologous expression of FMDV immunodominant epitopes and HSP70 in P. pastoris and the subsequent immune response in mice. Vet Microbiol 2007; 124:256-263.

45. Benabdesselem C, Barbouche MR, Jarboui MA, Dellagi K, Ho JL, Fathallah DM. High level expression of recombinant Mycobacterium tuberculosis culture filtrate protein CFP32 in Pichia pastoris. Mol Biotechnol 2007; 35:41-49.

46. Benabdesselem C, Fathallah DM, Huard RC, Zhu H, Jarboui MA, Dellagi K, et al. Enhanced patient serum immunoreactivity to recombinant Mycobacterium tuberculosis CFP32 produced in the yeast Pichia pastoris compared to Escherichia coli and its potential for serodiagnosis of tuberculosis. J Clin Microbiol 2006; 44:3086-3093.

47. Su CX, Duan XG, Wang XQ, Ren XF, Cao RB, Zhou B, et al. Fusion expression of O type foot-and-mouth diseases virus VP1 gene and HSP70 gene and induction of immune responses in mice. Sheng Wu Gong Cheng Xue Bao 2006; 22:733-736.